Thermo Fisher Scientific Signs Companion Diagnostic Agreement With Boehringer Ingelheim To Select Patients With NSCLC For Targeted Therapy Treatment
Portfolio Pulse from Benzinga Newsdesk
Thermo Fisher Scientific has announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim to develop CDx tests for identifying patients with non-small cell lung cancer (NSCLC) with specific genomic mutations. The collaboration will leverage the Oncomine Dx Express Test and the Oncomine Dx Target Test. The aim is to improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments.
October 19, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Thermo Fisher's partnership with Boehringer Ingelheim to develop diagnostic tests for lung cancer patients could potentially boost its revenues and strengthen its position in the healthcare sector.
The partnership with Boehringer Ingelheim could potentially increase Thermo Fisher's revenues as it will lead to the development of new diagnostic tests. This could also enhance Thermo Fisher's reputation in the healthcare sector, potentially attracting more partnerships and customers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100